Alnylam Pharmaceuticals, Inc.
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 844.29M | 1.04B | 1.83B | 2.25B | 3.71B | 65.2% | |
| Cost of Revenue | (140.14M) | (168.82M) | (310.41M) | (323.37M) | (677.17M) | 109.4% | |
Gross Profit | 704.14M | 868.60M | 1.52B | 1.92B | 3.04B | 57.8% | |
| Operating Expenses | |||||||
| Research & Development | (792.16M) | (883.01M) | (1.00B) | (1.13B) | (1.32B) | 17.6% | |
| Selling, General & Administrative | (620.64M) | (770.66M) | (795.65M) | (975.53M) | (1.21B) | 24.1% | |
| Depreciation & Amortization | (47.57M) | (44.47M) | (54.05M) | (56.67M) | (55.66M) | -1.8% | |
Operating Income (EBIT) | -708.65M | -785.07M | -282.18M | -176.88M | 501.58M | -383.6% | |
| Non-Operating Items | |||||||
| Interest Income | 1.58M | 24.81M | 95.56M | 121.99M | 111.47M | -8.6% | |
| Interest Expense | (143.02M) | (155.97M) | (121.22M) | (141.86M) | (252.63M) | 78.1% | |
| Other Income/Expenses (Net) | -143.49M | -341.92M | -151.34M | -200.49M | -178.43M | -11.0% | |
Income Before Tax | -852.14M | -1.13B | -433.52M | -377.38M | 323.15M | -185.6% | |
| Income Tax Expense | (680.00K) | (4.16M) | (6.72M) | (99.22M) | (9.40M) | -109.5% | |
Net Income | -852.82M | -1.13B | -440.24M | -278.16M | 313.75M | -212.8% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $-7 | $-9 | $-4 | $-2 | $2 | -209.6% | |
| Weighted Avg Shares Outstanding | 118.45M | 121.69M | 124.91M | 127.65M | 131.00M | 2.6% | |
| Weighted Avg Shares Outstanding (Diluted) | 118.45M | 121.69M | 124.91M | 127.65M | 134.68M | 5.5% | |
EBITDA | -661.56M | -926.56M | -258.24M | -178.85M | 557.24M | -411.6% |
Explore ALNY
ALNY in the Healthcare
Large Cap